Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Nephrology | Urology | Family Medicine
Disease Category: Prostate Cancer
Location: United States, IL

Clinical Trial Details

Overview

Research Study Summary

SWOG S0925 Phase II Randomized Study of Combined Androgen Deprivation Comprising Bicalutamide and Goserelin or Leuprolide Acetate With Versus Without Cixutumumab in Patients With Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer

Purpose

To compare the undetectable PSA rate (< 0.2 ng/mL) in patients with newly diagnosed hormone-sensitive metastatic prostate cancer treated with combined androgen deprivation comprising bicalutamide and goserelin or leuprolide acetate with versus without cixutumumab.

Patient Inclusion Criteria:

  • Histologically or cytologically confirmed adenocarcinoma of the prostate
  • Metastatic disease as evidenced by soft tissue and/or bony metastases, including ≥ 1 of the following:
    1. Visceral disease (liver, lung, or other viscera)
    2. Bone metastases to sites in either the axial (spine, pelvis, ribs, or skull) and/or the appendicular (clavicle, humerus, or femur) skeleton
    3. PSA ≥ 5 ng/mL within 90 days before initiation of androgen-deprivation therapy (ADT)
    4. No known brain metastases
    5. Brain imaging studies not required for patients with no neurologic signs or symptoms

Patient Exclusion Criteria:

  • No prior cytotoxic chemotherapy for metastatic prostate cancer
  • Prior cytotoxic chemotherapy with curative intent in the neoadjuvant or adjuvant setting is allowed
  • No prior treatment with agents that directly inhibit IGF or IGFR
  • No prior chimerized or murine monoclonal antibody therapy
  • No concurrent antiretroviral therapy for HIV-positive patients
  • No concurrent treatment with any of the following:
    1. Chemotherapy
    2. Hormonal therapy (other than the LHRH agonist and oral anti-androgen)
    3. Radiotherapy
    4. Immunotherapy
    5. Any other anticancer therapy
    6. 5-alpha reductase inhibitors (e.g., finasteride or dutasteride)
    7. Ketoconazole
    8. Diethylstilbestrol/DES
    9. Other estrogen-based therapy

To Learn more
Phase

2

Gender

Male

Age

N/A

Overall Status

Recruiting

Facility Type

N/A

Contact

Janeen V. Bazan, RN OCN BSN CCRP, Oncology Research Nurse Program Coordinator
Sherman Health
1425 North Randall Road
Elgin, IL 60123
Phone: 224-783-2907
Fax: 224-783-3071

View Map

Research Center Information: Sherman Health

If you would like to learn more about participating in this research study, please email the trial contact using the form below.

Name:
Address:
City:
State:
Zip/Postal Code:
Country:
Phone:
Email:  
Message:
 
Please leave this field empty.

CW ID: 183156

Date Last Changed: July 17, 2013


DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.